Glaxosmithkline Share News (GSK)

TOP NEWS: Glaxo's ViiV Gets Positive Results On Two-Drug HIV Treatment

GSK reports positive results from two-drug HIV regime study

(ShareCast News) - Pharmaceutical giant GlaxoSmithKline said it achieved positive results from a phase three HIV study, which assessed the efficiency of a two-drug regimen. ViiVHealthcare, which is majority owned by the company with stakes owned by Pfizer and Shionogi, said the first phase three stu

GSK boosts board-level science as new CEO prepares to take over

LONDON, Dec 19 (Reuters) - Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over. Incoming CEO Emma Walmsley, the first woman to lead a top global d

GlaxoSmithKline starts phase III study of asthma treatment

(ShareCast News) - GlaxoSmithKline has announced the start of a phase III study of its once-daily triple combination therapy fluticasone furoate/umeclidinium/vilanterol as a treatment for patients with asthma. The study, which will be conducted in partnership with Innoviva Inc, will compare the trea

Tuesday broker round-up

(ShareCast News) - British Land: Barclays reiterates overweight with a target price of 740p. GlaxoSmithKline: UBS reiterates neutral, 1600p target. Reckitt Benckiser: Jefferies reiterates buy with a 7750p target. GB Group: Berenberg reiterates buy with a 340p target. Great Portland Estates: Barcl

BUZZ-European Pharma: UBS shuffles recommendations

** UBS analysts say investors in healthcare stocks should seek exposure to oncology and new expensive drugs which displace older expensive drugs; avoid therapy areas at risk of becoming crowded and new drugs with high budget impact ** Brokerage double upgrades to "buy" from "sell" Novo Nord

BROKER RATINGS SUMMARY: Credit Suisse Raises Rio Tinto And Cuts BHP

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON, Dec 5 (Reuters) - GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse. Waterhouse, currently in charge of primary care wi

TOP NEWS: Glaxo's Relvar Ellipta Approved For COPD In Japan

Japan approves GSK's bronchitis and emphysema drug

(ShareCast News) - The Japanese government has approved GlaxoSmithKilne and Nasdaq-listed Innoviva's drug which treats chronic bronchitis and pulmonary emphysema. Japan's Ministry of Health, Labour and Welfare approved the use of Relvar, which relieves symptoms of chronic obstructive pulmonary disea

Thursday newspaper round-up: Pensions, Fitbit, Glaxo, Logica

(ShareCast News) - Labour has vowed to protect pensioner benefits, free bus passes and the winter fuel payment until 2025 in an attempt to dent the overwhelming support for the Conservative party among older voters. The £3bn-a-year commitment comes just one week after Philip Hammond, the chancellor,

GSK biotech asthma drug wins UK approval after extra price cut

LONDON, Dec 1 (Reuters) - GlaxoSmithKline's new injectable asthma drug Nucala has been recommended for use in Britain's state-run health service in the most severe patients, after the drugmaker provided further analyses on its use and made an additional price cut. The National Institute for

Injections, implants tested as new weapons to prevent HIV

* GSK to start large trials testing protective injection * Under-skin implants seen as promising long-term option * New HIV cases still running at 1.9 million annually By Ben Hirschler LONDON, Nov 29 (Reuters) - Scientists are taking the battle to prevent HIV to the next l

GlaxoSmithKline seeks European approval for shingles vaccine

(ShareCast News) - GlaxoSmithKline announced the regulatory submission of a marketing authorisation application to the European Medicines Agency for approval of its candidate shingles vaccine, Shingrix. The phase III clinical trial of the vaccine - for the prevention of shingles in people over 50 an

BUZZ-AstraZeneca: boosted by Liberum upgrade as Healthcare rallies

** AstraZeneca +1%, second-top riser on FTSE 100 in volume ** Liberum upgrades to "buy" v "hold" - with stock down 8 pct YTD, trading around 5-mth lows, risk/reward going into a rich seam of catalysts is now strongly to the upside ** Four major immuno-oncology readouts in 2017 (incl.